



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 13<sup>th</sup> November, 2021

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary, Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	---

Sub: Resubmission of Cash Flow Statement for the half year ended 30<sup>th</sup> September, 2021 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Ref:- BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN : INE829A01014.

Dear Sir/Madam,

This is in Continuation of our letter dated 12<sup>th</sup> November, 2021 regarding submission of Un-audited Financial Statements for the Quarter and half year ended on 30<sup>th</sup> September, 2021.

Pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulations, 2015, the Un-audited Financial Statements of the Company for the Quarter and Half Year ended on 30<sup>th</sup> September, 2021 along with the Statement of Assets and Liabilities, Cash Flow Statement, Segment Reporting and Limited Review Report in the PDF Format has been submitted in the prescribed time.

Further, we would like to inform that due to typographically error of wrong entry of profit before tax and failing to enter amount of Adjustments for provisions, current in the Cash Flow Statement, PDF file was wrongly uploaded on stock exchange, **however please note that there was no change in Un-audited financial results, Statement of assets & Liabilities and Segment Reporting, therefore we hereby submitting Revised Cash Flow Statement only for half year ended 30<sup>th</sup> September, 2021 after correction for your reference and records.**



*Further, we would like to inform that Company has submitted the corrected Un-audited financial statement for quarter and half year ended 30<sup>th</sup> September, 2021 along with cash flow statement in XBRL mode to the exchange.*

You are requested to kindly take on record the same.

Sorry for your inconvenience caused in this regard.

Thanking you,  
Yours Faithfully,

For Biofil Chemicals and Pharmaceuticals Limited



*Shikha*  
Shikha Khilwani  
Company Secretary & Compliance Officer



**Biofil Chemicals and Pharmaceuticals Limited**  
 Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)  
 CIN L24233MP1985PLC002709  
 Email Id:bcplcompliance@gmail.com Phone No.0731-2426718,  
 Website: www.biofilgroup.net

**Statement of cash flows for the year half year ended 30th Sept 2021**

Particulars	( Amount in Lakhs)	
	HALF YEAR ENDED ON 30.09.21	HALF YEAR ENDED ON 30.09.20
	Unaudited	Unaudited
<b>Cash flow from operating activities</b>		
Profit before tax	53.14	114.37
Adjustments to reconcile profit before tax to net cash used in operating activities		
Depreciation of property, plant and equipment	20.59	21.09
Finance cost	1.95	4.45
Impact Considered in OCI		
Net (gain)/ loss on derivative contracts on account of Ind AS adjustments		
Provision for doubtful advances/debts		
Working capital adjustments	75.68	139.91
Increase/ (Decrease) in Inventory		
(Increase)/ Decrease in Trade Receivable	324.59	59.12
(Increase)/ Decrease in other current assets	(914.20)	748.96
Increase/ (Decrease) in trade payables	99.56	(0.42)
Increase/ (Decrease) in other financial liabilities	424.31	(890.89)
Increase/ (Decrease) in other liabilities	(14.38)	4.06
Cash generated from operations	(5.53)	0.00
Adjustment for provision , Current	(9.98)	60.75
Net cash flows from operating activities	(14.49)	0.00
	(24.47)	60.75
<b>Cash flow from investing activities</b>		
Payment for purchase and construction of property, plant and equipment	(4.69)	(13.20)
Proceeds from sale of property, plant and equipment	0.00	0.00
(Increase)/ Decrease in other bank balances		
Interest received		
Net cash flows from investing activities	(4.69)	(13.20)
<b>Cash flow from financing activities</b>		
Increase/(decrease) in Borrowings	1.74	(38.99)
Deemed Investment by Holding Company		
Finance cost	(1.95)	(4.45)
Net cash flows from financing activities	(0.21)	(43.44)
Net increase / (decrease) in cash and cash equivalents	(29.36)	4.11
Cash and cash equivalents at the beginning of the year	44.05	25.60
Cash and cash equivalents at the end of the year	14.69	29.71
Increase / (Decrease) in cash and cash equivalents	(29.36)	4.11

Date : 12-11-2021  
 Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD

RAMESH SHAH  
 CHAIRMAN & MANAGING DIRECTOR  
 ( DIN: 00028819)

